Topics

Amgen's KRAS success has other drugmakers eager to follow

07:45 EDT 10 Jul 2019 | BioPharmaDive

Novartis, for one, will partner on a combination study with Mirati Therapeutics, which awaits the first clinical readout for its closely watched KRAS inhibitor.

Original Article: Amgen's KRAS success has other drugmakers eager to follow

NEXT ARTICLE

More From BioPortfolio on "Amgen's KRAS success has other drugmakers eager to follow"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...